The Skill to Heal. The Heart to Care.

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911




Latest Cancer News

EGFR Testing in Advanced Lung Cancer Appears Underutilized (04-28-2015)

The results of a recent survey suggest that nearly a quarter of advanced lung cancer patients fail to receive epidermal growth factor receptor (EGFR) testing before starting treatment. The recent development of drugs that target EGFR has expanded treatment... Continue Reading

Study Demonstrates Superiority Of Kyprolis® over Velcade® in Patients With Relapsed Multiple Myeloma (04-27-2015)

The results from a planned interim analysis of the Phase 3 head-to-head clinical trial ENDEAVOR evaluating Kyprolis® (carfilzomib in combination with low-dose dexamethasone versus Velcade® (bortezomib) and low-dose dexamethasone have demonstrated that... Continue Reading

The Importance of Awareness of Breast Density and Its Impact on Cancer Screening and Risk (04-23-2015)

Women in the United States may not be adequately aware of breast density and its complications. Legislation that requires providers to discuss a woman’s breast density is likely to help build awareness. These findings were reported in the Journal of... Continue Reading

More Effective Surgery for Colon Cancer with Laparoscopic versus Open Colectomy (04-22-2015)

Less invasive surgery for colon cancer with laparoscopic colectomy improves outcomes. These findings were reported in the Journal of the National Cancer Institute. Historically, surgical treatment for colon cancer involved a procedure called open colectomy... Continue Reading

What you Need to Know about Itching and Myeloproliferative Neoplasms (04-21-2015)

What you Need to Know about Itching and Myeloproliferative Neoplasms If you have been diagnosed with myelofibrosis or polycythemia vera, you may have experienced itching as a side effect. Itching occurs as a result of the activity of cytokines (small... Continue Reading

Keytruda® May Be More Effective than Yervoy® in Advanced Melanoma (04-20-2015)

Keytruda® (pembrolizumab) appears to outperform Yervoy® (ipilimumab) at initial treatment of patients with advanced melanoma. Pharmaceutical company Merck announced these Phase III clinical trial findings in a press release in March 2015. Melanoma is... Continue Reading

Important Clues in the Development of Aggressive Thyroid Cancer (04-16-2015)

New insight into how anaplastic thyroid cancer (ATC) grows and spreads may provide important direction in the development of treatment. These findings were published in the Journal of Clinical Endocrinology and Metabolism. The thyroid is a gland in the... Continue Reading

Radiofrequency Ablation in Barrett’s Esophagus May Prevent Esophageal Cancer (04-15-2015)

Treatment of Barrett’s esophagus with radiofrequency ablation appears to keep the condition from progressing to esophageal cancer. These findings were published in the Journal of the American Medical Association. Barrett’s esophagus is a pre-cancerous... Continue Reading

Jakafi® Provides Important Symptom Relief in Patients with Polycythemia Vera (04-14-2015)

A Phase III trial finds that Jakafi® (ruxolitinib) more effectively controls symptoms than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine. Polycythemia vera is a slow-growing... Continue Reading

Researchers Develop New Potential Drug for Rare Leukemia; Separate Study Suggests Possible Role in Prostate Cancer Treatment (04-13-2015)

Researchers Develop New Potential Drug for Rare Leukemia; Separate Study Suggests Possible Role in Prostate Cancer Treatment ANN ARBOR, Mich. — Researchers at the University of Michigan have developed a new drug candidate that shows potential in laboratory... Continue Reading

Unituxin® Approved for Treatment of Children with High-Risk Neuroblastoma (04-9-2015)

The U.S. Food and Drug Administration (FDA) has announced the first-ever drug approval for the treatment of children with high-risk neuroblastoma. In clinical trials Unituxin® (dinutuximab) has improved survival among children with this type of cancer... Continue Reading

Tasigna® Remains Superior to Gleevec® for Treatment of Newly Diagnosed Patients With Chronic Myeloid Leukemia (04-7-2015)

Tasigna® (nilotinib) remains superior to Gleevec® (imatinib) for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (PH+CML), according to the results of the six-year update from the ENESTnd trial which were presented... Continue Reading

Next Page »